Источники - взаимодействия между рекреационными наркотиками и антиретровирусными препаратами

References

1. Palella FJJ,Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten

GA, et al. Decliningmorbidity and mortality among patients with advanced

humanimmunodeficiency virus infection. HIV Outpatient Study

Investigators. N EnglJ Med 1998-338:853-60.

2. Cameron DW,Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath

C, et al. Randomisedplacebo-controlled trial of ritonavir in advanced

HIV-1 disease. TheAdvance HIV Disease Ritonavir Study

Group. Lancet1998-351:543-9.

3. Hammer SM, SquiresKE, Hughes MD, Grimes JM, Demeter LM, Currier

JS, et al. Acontrolled trial of two nucleoside analogues plus indinavir

in persons with humanimmunodeficiency virus infection and CD4 cell

counts of 200 percubic millimeter or less. AIDS Clinical Trials Group

320 Study Team. NEngl J Med 1997-337:725-33.

4. Van Cleef G,Fisher EJ, Polk RE. Drug interaction potential with inhibitors

of HIV protease.Pharmacotherapy 1997-17:774-8.

5.Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug

interactions inHIV-positive patients initiated on protease inhibitor therapy

(letter). AIDS1998-12:228-30.

6. von Moltke LL,Greenblatt DY, Grassi JM, Granda BW, Duan SX, Fogelman

SM, et al. Proteaseinhibitors as inhibitors of human cytochromes

P450: high riskassociated with ritonavir. J Clin Pharmacol 1998-38:106;

11.

7. von Moltke LL,Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX,

Daily JP, et al.Inhibition of cytochrome P450 isoforms by nonnucleoside

reverse transcriptaseinhibitors. J Clin Pharmacol 2001-41:85-91.

8. Deeks SG, Smith M,Holodniy M, Kahn JO. HIV-1 protease inhibitors: a

review forclinicians. JAMA 1997-277:145-53.

9. Barry M, GibbonsS, Back D, Mulcahy F. Protease inhibitors in patients

with HIV disease.Clinically important pharmacokinetic considerations.

Clin Pharmacokinet1997-32:194-209.

10. Piscitelli SC,Flexner C, Minor JR, Polis MA, Masur H. Drug interactions

in patients infectedwith HIV. Clin Infect Dis 1996-23:685-93.

11. Barry M, MulcahyF, Merry C, Gibbons S, Back D. Pharmacokinetics

and potentialinteractions amongst antiretroviral agents used to treat patients

with HIV infection.Clin Pharmacokinet 1999-36:289-304.

12. Tseng AL, FoisyMM. Management of drug interactions in patients with

HIV. Ann Pharmacother1997-31:1040-58.

13. Productmonograph. Sustiva (efavirenz).Princeton,NJ:Bristol Myers

Squibb Pharma,February 2002.

14. Patrick DM,Strathdee SA, Currie S, Pitchford W, Rekart ML, FitzGerald

M, et al. Incidenceof HIV in theVancouverIDU Study Cohort. Presented

at: 6th AnnualCanadian Conference on HIV/AIDS Research,Ottawa,

May 22–26, 1997.

15. Clarke S, Quah S,Courtney G,LyonsF, Bergin C, Mulcahy F. A rapidly

increasing incidenceof HIV infection in injecting drug users (IDU) in

Ireland(abstract). Presented at: 8th Conferenceon Retroviruses and Opportunistic

Infections,Chicago,February 4–8, 2001.

16. HIV/AIDSsurveillance report.Atlanta:Centers for Disease Control and

Prevention,2001-13:1- 41.

17. Geduld J,Archibald C. National trends of HIV and AIDS inCanada.

CanadaCommun Dis Rep 2000-26:193-201.

18. Henry JA, HillIR. Fatal interaction between ritonavir and MDMA.

Lancet 1998-352:1751-2.

19. Bertz RJ, GrannemanGR. Use of in vitro andin vivo data to estimate the

likelihood ofmetabolic pharmacokinetic interactions. Clin Pharmacokinet

1997-32:210-58.

20. Jacobs MR,O’Brien Fehr K. Drugs and drug abuse: a reference text.

Toronto: Alcoholism and Drug Addiction ResearchFoundation, 1987.

21. Tucker GT,Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al.

The demethylenationof methylenedioxymethamphetamine (“ecstasy”)

by debrisoquinehydroxylase (CYP2D6). Biochem Pharmacol 1994-47:

1151-6.

22. Colado MI,Williams JL,GreenAR. The hyperthermic and neurotoxic

effects of ‘Ecstasy’(MDMA) and 3,4 methylenedioxyamphetamine

(MDA) in the DarkAgouti (DA) rat, a model of the CYP2D6 poor metabolizer

phenotype. Br JPharmacol 1995-115:1281-9.

23. Kreth K, Kovar K,Schwab M, Zangar UM. Identification of the human

cytochromes P450involved in the oxidative metabolism of “Ecstasy”-related

drugs. BiochemPharmacol 2000-15:1563-71.

24. Sherlock K, WolffK, Hay AW, Conner M. Analysis of illicit ecstasy

tablets: implicationsfor clinical management in the accident and emergency

department. J AccidEmerg Med 1999-16:194-7.

25. Hesse LM, von MoltkeLL, Shader RI, Greenblatt DJ. Ritonavir,

efavirenz, andnelfinavir inhibit CYP2B6 activity in vitro: potential drug

interactions withbupropion. Drug Metab Dispos 2001-29:100-2.

26. Lin LY, Kumagai Y,Hiratsuka A, Narimatsu S, Suzuki T, Funae Y, et al.

Cytochrome P4502Disozymes catalyze the 4-hydroxylation of methamphetamine

enantiomers. DrugMetab Dispos 1995-23:610-4.

27. Geertsen S,FosterBC,Wilson DL, Cyr TD, Casley W. Metabolism of

methoxyphenamine and2-methoxyamphetamine in P4502D6-transfected

cells and cellpreparations. Xenobiotica 1995-25:895-906.

28. Lin LY, DiStefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, et

al. Oxidation ofmethamphetamine and methylenedioxymethamphetamine

by CYP2D6. Drug MetabDispos 1997-25:1059-64.

29. Lettieri JT, FungHL. Dose-dependent pharmacokinetics and hypnotic

effects of sodiumgamma-hydroxybutyrate in the rat. J Pharmacol Exp

Ther 1979-208:7-11.

30. Lettieri JT, FungHL. Absorption and first pass metabolism of 14C-gamma;

hydroxybutyric acid.Res Commun Chem Pathol Pharmacol 1976;

13:425-37.

31. Harrington RD,Woodward JA, Hooton TM, Horn JR. Life-threatening

interactions betweenHIV-1 protease inhibitors and the illicit drugs

MDMA andgamma-hydroxybutyrate. Arch Intern Med 1999-159:2221;

4.

32. White PF, Way WL,Trevor AJ. Ketamine — its pharmacology and therapeutic

uses. Anesthesiology1982-56:119-36.

33. Yanagihara Y,Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y,

et al. Involvement ofCYP2B6 in n-demethylation of ketamine in human

liver microsomes. DrugMetab Dispos 2001-29:887-90.

34. Loch JM, Potter J,Bachman KA. The influence ofanesthetic agents on

rat hepatic cytochromesP450 in vivo. Pharmacology 1995-50:146-53.

35. Menuguz A,Fortuna S, Lorenzini P, Volpe MT. Influence of urethane

and ketamine on rathepatic cytochrome P450 in vivo. Exp Toxicol

Pathol 1999-51:392-6.

36. Laurenzana EM,Owens SM. Metabolism of phencyclidine by human

liver microsomes. DrugMetab Dispos 1997-25:557-63.

37. Shelnutt SR, BadgerTM, Owens SM. Phencyclidinemetabolite irreversible

binding in the rat:gonadal steroid regulation and CYP2C11. J

Pharmacol Exp Ther1996-277:292-8.

38. Crowley JR,Hollenberg PF. Mechanism-based inactivation of rat liver

cytochrome P4502B1 byphencyclidine and its oxidative product, the

iminium ion. Drug MetabDispos 1995-23:786-93.

39. Inoue T,Niwaguchi T, Murata T. Effects of inducers and/or inhibitors on

metabolism oflysergic acid diethylamide in rat liver microsomes. Xenobiotica

1980-10:913-20.

40. Cai J, Henion J.Elucidation of LSD in vitro metabolism by liquid chromatography

and capillaryelectrophoresis coupled with tandem mass

spectrometry. J AnalToxicol 1996-20:27-37.

41. Iribarne C,Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement

of cytochrome P4503A4 enzyme in the N-demethylation of

methadone in humanliver microsomes. Chem Res Toxicol 1996-9:365;

73.

1610 The Annals ofPharmacotherapy 2002 October, Volume36 theannals.com

T Antoniou and AL Tseng

42. Foster DJ,Somogyi AA, Bochner F. Methadone N-demethylation in human

liver microsomes:lack of stereoselectivity and involvement of

CYP3A4. Br J ClinPharmacol 1999-47:403-12.

43. Eap CB, Broly F,Mino A, Hammig R, Deglon JJ, Uehlinger C, et al.Cytochrome

P450 2D6 genotype andmethadone steady-state concentrations.

J ClinPsychopharmacol 2001-21:229-34.

44. Gerber JG, RhodesRJ. Cytochrome P450 2B6 metabolizes methadone

preferentially andstereospecifically. An explanation of drug interaction

with antiretroviraldrugs (abstract 2.2). Presented at: First International

Workshop on ClinicalPharmacology of HIV Therapy, Noordwijk, the

Netherlands,March 30–31, 2000:14.

45. Clarke SM,Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,

et al. Thepharmacokinetics of methadone in HIV-positive patients receiving

the non-nucleosidereverse transcriptase inhibitor efavirenz. Br J

Clin Pharmacol2001-51:213-7.

46. Heelon MW, Meade LB. Methadone withdrawalwhen starting an

antiretroviralregimen including nevirapine. Pharmacotherapy 1999-19:471;

2.

47. Marzolini C,Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB.

Efavirenz decreasesmethadone blood concentrations. AIDS 2000-14:1291;

2.

48. Pinzani V,Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal

symptoms withnevirapine and efavirenz (letter). Ann Pharmacother

2000-34:405-7.

49. Staszewski S,Haberl A, Gute P, Nisius G, Miller V, Carlebach A.

Nevirapine/didanosine/lamivudineonce daily in HIV-1 infected intravenous

drug users. AntiviralTher 1998-3:55-6.

50. Altice FL,Friedland GH, CooneyE. Nevirapine inducedopiate withdrawal

among injection drugusers with HIV infection receiving

methadone. AIDS1999-13:957-62.

51. Otero MJ, FuertesA, Sanchez R, Luna G. Nevirapine-induced withdrawal

symptoms in HIVpatients on methadone maintenance programme:

an alert. AIDS1999-13:1004-5.

52. Geletko SM,Erickson AD. Decreased methadone effect after ritonavir

initiation.Pharmacotherapy 2000-20:93-4.

53. Hsyu PH,Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic

and pharmacodynamicinteractions between nelfinavir and methadone

(abstract 87).Presented at: 7th Conference on Retroviruses and Opportunistic

Infections,San Francisco, January30–February 2, 2000.

54. Gerber JG,Rosenkranz S, Segal Y, Aberg J, D’Amico R, Mildvan D, et

al. The effect ofritonavir/saquinavir on the stereoselective pharmacokinetics

of methadone: resultsof AIDS clinical trials group (ACTG) 401. J

Acq Immune Def Synd2001-27:153-60.

55. Hendrix C, WakefordJ, Wire MB, Bigelow G, Cornell E, Christopher J,

et al.Pharmacokinetic and pharmacodynamic evaluation of methadone

enantiomers followingco-administration with amprenavir in opioid-dependent

subjects (abstract1649). Presented at: 40th Interscience Conference

on AntimicrobialAgents and Chemotherapy,Toronto,September

17–20, 2000:335.

56. Maroldo L,Manocchio S, Artenstein A, Weiss W. Lack of effect of nelfinavir

mesylate onmaintenance methadone dose requirement (abstract

WePeB4120). Presentedat: XIII International AIDS Conference,Durban,

South Africa,July 9–14, 2000:60.

57. McCance-Katz EF,Farber S, Selwyn PA, O’Connor A. Decrease in

methadone levels withnelfinavir mesylate (letter). Am J Psychiatry

2000-157:481.

58. Beauverie P,Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic

drug monitoring ofmethadone in HIV-infected patients receiving

protease inhibitors.AIDS 1998-12:2510-1.

59. Rainey PM,Friedland G, McCance-Katz EF, Andrews L, Mitchell SM,

Charles C, et al.Interaction of methadone with didanosine and stavudine.

J Acq Immune Def Synd2000-24:241-8.

60. Schwartz EL,Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland

GH. Pharmacokineticinteractions of zidovudine and methadone in intravenous

drug–using patientswith HIV infection. JAcq Immune Def

Synd 1992-5:619-26.

61. McCance-Katz EF,Rainey PM, Jatlow P, Friedland G. Methadone effects

on zidovudinedisposition (AIDS clinical trials group 262). J Acq

Immune Def Synd1998-18:435- 43.

62. Sellers E, Lam R,McDowell J, Corrigan B, Hedayetullah N, Somer G,

et al. Thepharmacokinetics of abacavir and methadone following coadministration:

CNAA1012 (abstract663). Presented at: 39th Interscience

Conference onAntimicrobial Agents and Chemotherapy,SanFrancisco,

September 26–28,1999:25.

63. Booker B, SmithP, Forrest A, Difrancesco R, Morse G, Cottone P, et al.

Lack of effect ofmethadone (MET) on the pharmacokinetics (PK) of

delavirdine (DLV)& N-delavirdine (abstract A 490). Presentedat: 41st

InterscienceConference on Antimicrobial Agents and Chemotherapy,

Chicago,December 16–19, 2001:14.

64. Boffito M,Rossati A, Dal Conte I, Reynolds H, Gibbons S, Back D, et

al. Opiate withdrawalsyndrome in new efavirenz recipients under

methadone maintenanceregimen (abstract). Presented at: 1st IAS Conference

on HIV Pathogenesisand Treatment,Buenos Aires,July 8–11,

2001.

65. Smith PF, BookerBM, Difrancesco R, Morse GD, Cottone PF, Murphy

MK, et al. Effect ofmethadone or LAAM on the pharmacokinetics of

nelfinavir & M8(abstract A- 491). Presented at: 41st Interscience Conference

on AntimicrobialAgents and Chemotherapy,Chicago,December

16–19, 2001:14.

66. Brown LS,Chu M, Aug C, Dabo S. The use of nelfinavir and twonucleosides

concomitantly withmethadone is effective and well-tolerated in

HepC co-infectedpatients (abstract I-206). Presented at: 41st Interscience

Conference onAntimicrobial Agents and Chemotherapy,Chicago,

December 16–19, 2001:311.

67.Shelton MJ, Cloen D, Berenson C, Esch A,Brewer J, Hewitt R. Pharmacokinetics

(PK) of once daily(QD) saquinavir/ritonavir (SQV/RTV): effects

on unbound methadoneand -acidglycoprotein (AAG) (abstract

A-492). Presented at:41st Interscience Conference on Antimicrobial

Agents and Chemotherapy,Chicago,December 16–19, 2001:14.

68. Clarke SM,Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,

et al.Pharmacokinetic interactions of nevirapine and methadone and

guidelines for use ofnevirapine to treat injection drug users. Clin Infect

Dis 2001-33:1595-7.

69. Cantilena L,McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al.

Lack of apharmacokinetic interaction between indinavir and methadone

(abstract PI-74).Clin Pharmacol Ther 1999-65:135.

70. Clarke S, MulcahyF, Bergin C, Reynolds H, Boyle N, Barry MG, et al.

Absence of opioidwithdrawal symptoms in patients receiving methadone

and the proteaseinhibitor lopinavir–ritonavir. Clin Infect Dis 2002-34:

1143-5.

71. Munsiff AV, PatelJ. Regimens with once daily ritonavir + Fortovase are

highly effective inPI-experienced HIV-HCV co-infected patients on

methadone (abstract684). Presented at: 39th Annual Meeting of the Infectious

Diseases Society ofAmerica,San Francisco,October 25–28, 2001.

72. Friedland G,Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz

E. Pharmacokinetics(pK) of didanosine (ddI) from encapsulated enteric

coated beadformulation (EC) vs chewable tablet formulation in patients

(pts) on chronicmethadone therapy (abstract TuPeB4548). Presented at:

XIV InternationalAIDS Conference,Barcelona,July 7–12, 2002,vol

1:402-3.

73. Guibert A, FurlanV, Martino J, Taburet AM. In vitro effect of HIV protease

inhibitors onmethadone metabolism (abstract). Presented at: 37th

InterscienceConference on Antimicrobial Agents and Chemotherapy,

Toronto, September 28–October 1, 1997.

74. Hsu A, GrannemanGR, Carothers L, Dennis S, Chiu Y-L,ValdesJ, et al.

Ritonavir does notincrease methadone exposure in healthy volunteers

(abstract 342).Presented at: 5th Conference on Retroviruses and Opportunistic

Infections,Chicago,February 1–5, 1998.

75. Boulton DW,Arnaud P, DeVane CL. A single dose of methadone inhibits

cytochrome P- 4503Aactivity in healthy volunteers as assessed by

the urinary cortisolratio. Br J Clin Pharmacol 2001-51:350-4.

76. Iribarne C,Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of

methadone withsubstrates of human hepatic cytochrome P450 3A4.

Toxicology1997-117:13-23.

77. Wu D, Otton SV,Sproule BA, Busto U, Inaba T, Kalow W, et al. Inhibition

of human cytochromeP450 2D6 (CYP2D6) by methadone. Br J

Clin Pharmacol1993-35:30-4.

78. Zhang KE, Wu E,Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating

metabolites of thehuman immunodeficiency virus protease inhibitor

nelfinavir in humans:structural identification, levels in plasma,

and antiviralactivities. Antimicrob Agents Chemother 2001-45:1086-93.

79. Edwards DJ,Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics

of pethidine. ClinPharmacokinet 1982-7:421-33.

80. Zhang J, BurnellJC, Dumaual N, Bosron WF. Binding and hydrolysis of

meperidine by humanliver carboxylesterase hCE-1. J Pharmacol Exp

Ther 1999-290:314-8.

81. Piscitelli S,Rock-Kress D, Bertz R,PauA, Davey R. The effect of ritonavir

on thepharmacokinetics of meperidine and normeperidine. Pharmacotherapy

2000-20:549-53.

Recreational Drug–Antiretroviral Agent Interactions

The Annals of Pharmacotherapy 2002 October, Volume 36 1611 theannals.com

82. Dayer P,Desmeules J, Striberni R. In vitro forecasting of drugs that

may interfere withcodeine bioactivation. Eur J Drug Metab Pharmacokinet

1992-17:115-20.

83. Poulsen L, BrosenK, Arendt-Neilsen L, Gram LF, Elbaek K, Sindrup

SH. Codeine andmorphine in extensive and poor metabolizers of

sparteine:pharmacokinetics, analgesic effect and side effects. Eur J

Clin Pharmacol1996-51:289-95.

84. Caraco Y,Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine Ndemethylation:

cosegregation withcytochrome P4503A4 activity. Drug

Metab Dispos1996-24:761-4.

85. Yue QY, Sawe J.Different effects of inhibitors on the O- and Ndemethylation

of codeine in humanliver microsomes. Eur J Clin Pharmacol

1997-1997:41-7.

86. Caraco Y, Sheller J,Wood AJ. Pharmacogeneticdeterminants of

codeine induction byrifampin: the impact on codeine’s respiratory, psychomotor

and miotic effects. JPharmacol Exp Ther 1997-281:330-6.

87. Caraco Y, Sheller J,Wood AJ. Pharmacogeneticdetermination of the

effects of codeineand prediction of drug interactions. J Pharmacol Exp

Ther1996-278:1165-74.

88. Heiskanen T,Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the

pharmacokinetics andpharmacodynamics of oxycodone. Clin Pharmacol

Ther 1998-64:603-11.

89. Coffman BL, RiosGR, King CD, Tephly TR. Human UGT2B7 catalyzes

morphineglucuronidation. Drug Metab Dispos 1997-25:1-4.

90. Fromm MF,Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, et al.

Loss of analgesiceffect of morphine due to coadministration of rifampin.

Pain 1997-72:261-7.

91. Osborne R, JoelS, Trew D, Slevin M. Analgesic activity of morphine;

6-glucuronide(letter). Lancet 1988-1:828.

92. Chaisson MA,Stoneburner RL, Hildebrandt DS,Ewing WE,Telzak

EE, Jaffe HW.Heterosexual transmission of HIV-1 associated with the

use of smokablefreebase cocaine (crack). AIDS 1991-5:1121-6.

93. Edlin BR, IrwinKL, Faruque S, McCoy CB, Word C, Serrano Y, et al.

Intersectingepidemics — crack cocaine use and HIV infection among

inner-city youngadults. Multicenter Crack Cocaine and HIV Infection

Study Team. N Engl JMed 1994-331:1422-7.

94. Nuttbrock L, RosenblumA, Magura S, McQuistion HL, Joseph H. The

association betweencocaine use and HIV/STDs among soup kitchen

attendees inNew York City. J Acq Immune Def Synd 2000-25:86-91.

95. Inaba T, StewartDJ, Kalow W. Metabolism of cocaine in man. Clin

Pharmacol Ther1978-23:547-52.

96. Cone EJ, TsadikA, Oyler J, Darwin WD. Cocaine metabolism and urinary

excretion afterdifferent routes of administration. Ther Drug Monit

1998-20:556-60.

97. Stewart DJ, InabaT, Lucassen M, Kalow W. Cocaine metabolism: cocaine

and norcocainehydrolysis by liver and serum esterases. Clin

Pharmacol Ther1979-25:464-8.

98. Leduc BW,Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt

DJ. Norcocaine and N-hydroxynorcocaine formation in humanliver

microsomes: role ofcytochrome P- 450 3A4. Pharmacology 1993-46:

294-300.

99. Ladona MG,Gonzalez ML, Rane A, Peter RM, de la Torre R. Cocaine

metabolism in humanfetal and adult liver microsomes is related to cytochrome

P450 3A expression.Life Sci 2000-68:431- 43.

100. Hoffman RS, HenryGC, Howland MA, Weisman RS, Weil L, Goldfrank

LR. Associationbetween life-threatening cocaine toxicity and

plasma cholinesteraseactivity. Ann Emerg Med 1992-21:247-53.

101. Ndikum-MofforFM, Schoeb TR, Roberts SM. Liver toxicity from norcocaine

nitroxide, an N-oxidative metabolite of cocaine. JPharmacol

Exp Ther1998-284:413-9.

102. Roberts SM,Harbison RD, JamesRC. Human microsomal N-oxidative

metabolism ofcocaine. Drug Metab Dispos 1991-19:1046-51.

103. Pellinen P,Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen

O, et al. Cocaine N-demethylation and the metabolism-relatedhepatotoxicity

can be prevented bycytochrome P450 3A inhibitors. Eur J

Pharmacol1994-270:35- 43.

104. Lockridge O,Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis

of diacetylmorphine(heroin) by human serum cholinesterase. J

Pharmacol Exp Ther1980-21:1-8.

105. Inturrisi CE, MaxMB, Foley KM, Schultz M, Shin SU, Houde RW.

The pharmacokineticsof heroin in patients with chronic pain.N EnglJ

Med 1984-310:1213-7.

106. Kamendulis LM,Brzezinski MR, Pindel EV, Bosron WF, Dean RA.

Metabolism of cocaineand heroin is catalyzed by the same human liver

carboxylesterases. JPharmacol Exp Ther 1996-279:713-7.

107. Jenkins AJ,Keenan RM, Henningfield JE, Cone EJ. Pharmacokinetics

and pharmacodynamicsof smoked heroin. J Anal Toxicol 1994-18:317;

30.

108. Busto UE.Benzodiazepines: the science and the myths. Can J Clin

Pharmacol1999-6:185-6.

109. Kronback T,Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation

of midazolam andtriazolam by human liver cytochrome P450IIIa4.

Mol Pharmacol1989-36:89-96.

110. VenkatakrishnanK, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam

is another substratefor human cytochrome P450-3A isoforms

(letter). J ClinPsychopharmacol 1998-18:256.

111. Frye R, Bertz R,Granneman GR, Qian J, Lamm J, Dennis S, et al. Effect

of ritonavir on thepharmacokinetics and pharmacodynamics of alprazolam

(abstract A59).Presented at: 37th Interscience Conference on

Antimicrobial Agentsand Chemotherapy,Toronto,September 28–October

1, 1997.

112. Greenblatt D,Moltke L, Harmatz J, Durol AL, Daily JP, Graf JA, et al.

Alprazolam–itonavirinteraction: implications for product labeling. Clin

Pharmacol Ther2000-67:335- 41.

113. Palkama VJ,Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir

on thepharmacokinetics and pharmacodynamics of oral and intravenous

midazolam. ClinPharmacol Ther 1999-66:33-9.

114. Merry C, MulcahyF, Barry M, Gibbons S, Back D. Saquinavir interaction

with midazolam:pharmacokinetic considerations when prescribing

protease inhibitorsfor patients with HIV disease (letter). AIDS 1997-11:

268-9.

115. Greenblatt DJ,von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf

JA, et al.Differential impairment of triazolam and zolpidem clearance

by ritonavir. J AcqImmune Def Synd 2000-24:129-36.

116. Greenblatt DJ,von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive

impairment oftriazolam and alprazolam clearance by short-term

low-dose ritonavir:the clinical dilemma of concurrent inhibition and

induction. J ClinPsychopharmacol 1999-19:293-6.

117. Seree EJ, PisanoPJ, Placidi M, Rahmani R, Barra YA. Identification of

the human and animalhepatic cytochromes P450 involved in clonazepam

metabolism. FundamClin Pharmacol 1993-7:69-75.

118. Hesse LM,Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt

DJ. CYP3A4 is themajor CYP isoform mediating the in vitro hydroxylation

and demethylation offlunitrazepam. Drug Metab Dispos 2001-29:

133- 40.

119. Ono S, HatanakaT, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ,

et al. Human livermicrosomal diazepam metabolism using cDNA expressed

cytochrome P450s:role of CYP2B6, 2C19 and the 3A subfamily.

Xenobiotica1996-26:1155-66.

120. Jung F,Richardson TH, Raucy JL,Johnson EF. Diazepam metabolism

by cDNA-expressedhuman 2C P450s: identification of P4502C18 and

P4502C19 as low K(M)diazepam N-demethylases. Drug Metab Dispos

1997-25:133-9.

121. Patwardhan RV,Yarborough GW, Desmond PV, Johnson RF, Schenker

S, Speeg KVJ.Cimetidine spares the glucuronidation of lorazepam and

oxazepam.Gastroenterology 1980-79:912-6.

122. Ghabrial H,Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen

KJ, et al. Theeffects of age and chronic liver disease on the elimination

of temazepam. Eur JClin Pharmacol 1986-30:93-7.

123. HealthCanada.Canada’salcohol and other drugs survey. 1995-77:1-6.

124. Lemberger L.Tetrahydrocannabinol metabolism in man. Drug Metab

Dispos 1972-1:461-8.

125. Lemberger L, WeissJL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon

PV. Delta-9-tetrahydrocannabinol.Temporal correlation of the psychologic

effects and bloodlevels after various routes of administration. N

Engl J Med1972-30:685-8.

126. Bornheim LM,Lasker JM, Raucy JL. Human hepatic microsomal metabolism

of delta1-tetrahydrocannabinol. Drug Metab Dispos 1992-20:

241-6.

127. Watanabe K,Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement

of CYP2C in themetabolism of cannabinoids by human hepatic

microsomes from anold woman. Biol Pharm Bull 1995-18:1138;

41.

128. Kosel BW, AweekaFT, Benowitz NL, Shade SB, Hilton JF, Lizak PS,

et al. The effects ofcannabinoids on the pharmacokinetics of indinavir

and nelfinavir. AIDS2002-16:543-50.

129. McDowell JA,Chittick GE, Pilati-Stevens C, Edwards KD, Stein DS.

Pharmacokineticinteraction of abacavir (1592U89) and ethanol in human

immunodeficiencyvirus–infected adults. Antimicrob Agents

Chemother2000-44:1686-90.

1612 The Annals ofPharmacotherapy 2002 October, Volume36 theannals.com

T Antoniou and AL Tseng

Recreational Drug–Antiretroviral Agent Interactions

The Annals of Pharmacotherapy 2002 October, Volume 36 1613 theannals.com

130. Tanaka E, MisawaS. Pharmacokinetic interactions between acute alcohol

ingestion and singledoses of benzodiazepines, and tricyclic and

tetracyclicantidepressants — an update. J Clin Pharm Ther 1998-23:

331-6.

131. Klotz U, AmmonE. Clinical and toxicological consequences of the inductive

potential of ethanol.Eur J Clin Pharmacol 1998-54:7-12.

132. Kostrubsky VE,Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair

JF. Ethanol andisopentanol increase CYP3A and CYP2E in primary

cultures of humanhepatocytes. Arch Biochem Biophys

1995-322:516-20.

133. Hsu A, Bertz R,Granneman GR. Assessing ritonavirdose effect on the

pharmacokineticparameters of protease inhibitors (abstract 3.3). Presented

at: 2nd InternationalWorkshop on Clinical Pharmacology of

HIV Therapy,Noordwijk, theNetherlands,April 2– 4, 2001.

134. Degen O,Kurowski M, Van Lunzen J, Schewe CK, Stellbrink H. Amprenavir

and ritonavir:intraindividual comparison of different doses

and influence ofconcomitant NNRTI on steady-state pharmacokinetics

in HIV-infectedpatients (abstract 739). Presented at: 8th Conference on

Retroviruses andOpportunistic Infections,Chicago,February 4–8,

2001:267.